The Scottish Medicines Consortium (SMC) has resumed issuing its monthly advice on newly licensed medicines.
Hydroxycarbamide oral solution (Xromi®) has been accepted for restricted for use in the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 2 years of age. The restriction limits use to children who are too young to be able to swallow capsules / tablets and adults and adolescents who have difficulty in swallowing solid oral dosage forms.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.